Dataset Information


In vivo efficacy of the combination of ciprofloxacin and cefotaxime against Vibrio vulnificus sepsis.



The in vivo efficacy of a cefotaxime-ciprofloxacin combination against Vibrio vulnificus and the effects on rtxA1 expression of commonly used antibiotics are unknown.


In vitro time-kill studies were performed to evaluate synergism. Female BALB/c mice were injected subcutaneously with 1×10(7) or 1×10(8) cfu of V. vulnificus. Antibiotic therapy was initiated at 2 h after inoculation in the following four therapy groups: cefotaxime; ciprofloxacin; cefotaxime-plus-ciprofloxacin; and cefotaxime-plus-minocycline. The cytotoxicity of V. vulnificus for HeLa cells was measured using the lactate dehydrogenase assay; rtxA1 transcription was measured in a transcriptional reporter strain using a ?-galactosidase assay.


In vitro time-kill assays exhibited synergism between cefotaxime and ciprofloxacin. In the animal experiments, the 96-h survival rate for the cefotaxime-plus-ciprofloxacin group (85%; 17/20) was significantly higher than that of the cefotaxime-plus-minocycline (35%; 7/20) and cefotaxime alone (0%; 0/20) groups (P<0.05 for both). Bacterial counts in the liver and spleen were significantly lower in the cefotaxime-plus-ciprofloxacin group 24 and 48 h after treatment, relative to the other groups. At sub-inhibitory concentrations, ciprofloxacin inhibited more effectively rtxA1 transcription and mammalian cell cytotoxicity than either minocycline or cefotaxime (P<0.05 for both).


Ciprofloxacin is more effective at reducing rtxA1 transcription and subsequent cytotoxicity than either minocycline or cefotaxime, and the combination of ciprofloxacin and cefotaxime was more effective in clearing V. vulnificus in vivo than previously used regimens. These data suggest that the combination of ciprofloxacin and cefotaxime is an effective option for the treatment of V. vulnificus sepsis in humans.


PROVIDER: S-EPMC4076242 | BioStudies | 2014-01-01

REPOSITORIES: biostudies

Similar Datasets

2011-01-01 | S-EPMC3133160 | BioStudies
2019-01-01 | S-EPMC6598492 | BioStudies
2018-01-01 | S-EPMC5862816 | BioStudies
2016-01-01 | S-EPMC4801212 | BioStudies
2007-01-01 | S-EPMC1932941 | BioStudies
2010-01-01 | S-EPMC2935016 | BioStudies
2020-01-01 | S-EPMC7409051 | BioStudies
1000-01-01 | S-EPMC4249331 | BioStudies
2018-01-01 | S-EPMC5958221 | BioStudies
2011-01-01 | S-EPMC3029691 | BioStudies